Skip to main content

Study Finds That an SGLT Inhibitor Is the First of Its Kind to Significantly Reduce Heart Attacks and Strokes

title

Sotagliflozin, a drug approved by the FDA to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients.

Learn More